从肠道微生物群对抗肝细胞癌的潜在目标代谢物:网络药理学和分子对接研究
Sehar Aslam1, Muhammad Qasim1, Fatima Noor1,2
1Department of Bioinformatics and Biotechnology, Government College University Faisalabad, Faisalabad, Pakistan.
肠道微生物群代谢物显示出治疗肝细胞癌 (HCC) 的潜力. 这项研究确定了关键代谢物及其标,为HCC药物开发提供了新的途径.
科学领域:
- 在瘤学瘤学.
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝细胞癌 (HCC) 是一个主要的全球健康问题,死亡率高.
- 肠道微生物群代谢物在癌症治疗中的作用是有希望的,但尚未完全理解.
- 识别特定的活性代谢物及其点对于开发新型HCC治疗非常重要.
研究的目的:
- 通过网络药理方法识别强效肠道微生物群代谢物及其肝细胞癌 (HCC) 治疗的关键标.
- 探索这些代谢物对HCC的治疗潜力.
主要方法:
- 网络药理学方法整合了gutMGene,瑞士目标预测和GeneCards数据库.
- 范图分析以确定代谢物和HCC之间的重叠目标.
- 构建一个代谢物-点路径网络.
- 分子对接以验证代谢物-标结合亲和力.
主要成果:
- 确定了五种主要代谢物:p-cresol糖化物,secoisolariciresinol,糖醇酸,醇和酸.
- 确定了AKT1,EGFR,ALB和TNF作为HCC的潜在治疗点.
- 通过分子对接,验证了已识别的代谢物与它们的标蛋白之间的显著结合亲和力.
- 揭示了多个信号通路和生物过程,表明对HCC的预防作用.
结论:
- 肠道微生物群的代谢物,包括p-cresol糖胺,secoisolariciresinol,糖醇酸,醇和酸,显示出对HCC的治疗潜力.
- AKT1,EGFR,ALB和TNF被确定为HCC治疗的关键标.
- 这项研究为开发基于肠道微生物群代谢物的新型抗HCC药物提供了基础.
更多相关视频
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
相关概念视频
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Hepatic Drug Clearance: Role of Transporters
Drug Biotransformation: Overview
